MedTrace Logo

Evaluation of Two Levels of Frequency of Repositioning in the Reduction of Pressure Ulcers

NCT04604665 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3300

Last updated 2024-01-22

No results posted yet for this study

Summary

PENFUP FASE 2, It is a multicenter study by parallel conglomerates, planned in order to evaluate the efficacy between two levels of frequency of postural change in intensive care units for adults of hospitals in various regions of Colombia.

Conditions

  • Critical Illness

Interventions

OTHER

High frequency postural change

Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call "high-frequency" to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs.

OTHER

Conventional care

Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.

Sponsors & Collaborators

  • Universidad Autónoma de Bucaramanga

    collaborator OTHER

  • Fundación Cardioinfantil Instituto de Cardiología

    lead OTHER

Principal Investigators

  • Olga L Cortés, PhD · Fundación Cardioinfantil Instituto de Cardiología

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-10
Primary Completion
2023-12-10
Completion
2023-12-10

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04604665 on ClinicalTrials.gov